China Pituitary Disease Registry (CAPASITY)

NCT04713293 | Unknown

• 1 other identifier: 1.0/20200606
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

Epidemiologic studies have revealed a tremendous increase in the prevalence of pituitary disease and related mortality worldwide. In order to meet all the challenges in the treatment of pituitary disease in China, CAPASITY was founded in 2020. The objective of CAPASITY is to launch a pituitary disease management model based on the Internet health information platform. It allows the application and evaluation of pituitary disease treatment strategies at multiple centers. The proprietary electronic medical database will help the dynamic big-data analysis in epidemiology of pituitary disease, diagnosis, and treatment.

Conditions

Pituitary Disease

Keywords

Pituitary Disease; Pituitary Adenoma

Outcome Measures

Primary Outcomes (2)

• percentage of functional pituitary adenoma

  percentage of PRLoma, GHoma, ACTHoma, and etc

  through study completion, an average of 1 year

• remission and recurrence rate of pituitary surgery

  treatment outcome of pituitary adenoma. Results will be dichotomized as remission, persistence or recurrence.

  through study completion, an average of 1 year

Secondary Outcomes (11)

• concentration of GH

  through study completion, an average of 1 year

• concentration of IGF-1

  through study completion, an average of 1 year

• concentration of PRL

  through study completion, an average of 1 year

• concentration of ACTH

  through study completion, an average of 1 year

• concentration of cortisol

  through study completion, an average of 1 year

Eligibility Criteria

• Age: 14 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with pituitary disease

You may qualify if:

• Age ≥ 18 years old and ≤ 75 years
• Patients diagnosed with pituitary adenomas, and other pituitary diseases
• Pituitary adenomas resected by transsphenoidal surgery were identified by histological diagnoses.
• Gender: males and females
• Provide written informed consent
• Satisfactory compliance

You may not qualify if:

• Patients with significantly reduced life expectancy (less than 2 years)
• With Drug abuse
• With AIDS or syphilis or infectious diseases such as viral tuberculosis in active phase at enrollment

Sponsors & Collaborators

• Shanghai Jiao Tong University School of Medicine: lead

Study Sites (1)

National Metabolic Management center

Shanghai, Shanghai Municipality, 200025, China

RECRUITING

MeSH Terms

Conditions

Pituitary Diseases; Pituitary Neoplasms

Condition Hierarchy (Ancestors)

Hypothalamic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Endocrine System Diseases; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Hypothalamic Neoplasms; Supratentorial Neoplasms; Brain Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms

Study Officials

• Weiqing Wang, MD, PHD

  National Metabolic Management center (Shanghai)

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Weiqing Wang, MD, PHD

CONTACT

008621-64370045; wqingw61@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PhD, MD, Head of Department of Endocrine and Metabolism, Shanghai Jiaotong University School of Medicine, Chinese National Clinical Research Center for Endocrine and Metabolic Diseases (Shanghai)

Study Record Dates

• First Submitted: December 31, 2020
• First Posted: January 19, 2021
• Study Start: July 26, 2020
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: January 19, 2021

Record last verified: 2021-01

Locations

CN (1)